CO2020004202A2 - Compuestos químicos - Google Patents

Compuestos químicos

Info

Publication number
CO2020004202A2
CO2020004202A2 CONC2020/0004202A CO2020004202A CO2020004202A2 CO 2020004202 A2 CO2020004202 A2 CO 2020004202A2 CO 2020004202 A CO2020004202 A CO 2020004202A CO 2020004202 A2 CO2020004202 A2 CO 2020004202A2
Authority
CO
Colombia
Prior art keywords
compounds
chemical compounds
hepatitis
specifically
virus
Prior art date
Application number
CONC2020/0004202A
Other languages
English (en)
Inventor
Martin R Leivers
John G Catalano
Pek Yoke Chong
Hamilton D Dickson
Jason Gordon Weatherhead
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CO2020004202A2 publication Critical patent/CO2020004202A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Abstract

Compuestos, específicamente del virus de la hepatitis B o de los inhibidores del virus de la hepatitis D, más específicamente compuestos que inhiben el antígeno HBe y el antígeno HBs en un sujeto, para el tratamiento de infecciones virales, y métodos para preparar y usar tales compuestos.
CONC2020/0004202A 2017-10-05 2020-04-03 Compuestos químicos CO2020004202A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568633P 2017-10-05 2017-10-05
US201762570509P 2017-10-10 2017-10-10
US201862681146P 2018-06-06 2018-06-06
US201862683859P 2018-06-12 2018-06-12
PCT/IB2018/057767 WO2019069293A1 (en) 2017-10-05 2018-10-05 CHEMICAL COMPOUNDS

Publications (1)

Publication Number Publication Date
CO2020004202A2 true CO2020004202A2 (es) 2020-04-24

Family

ID=64049476

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0004202A CO2020004202A2 (es) 2017-10-05 2020-04-03 Compuestos químicos

Country Status (25)

Country Link
US (2) US20200255428A1 (es)
EP (2) EP4180431A1 (es)
JP (1) JP7248665B2 (es)
KR (1) KR20200065024A (es)
CN (2) CN111433206B (es)
AU (2) AU2018344926A1 (es)
BR (1) BR112020006456A2 (es)
CA (1) CA3078312A1 (es)
CL (1) CL2020000912A1 (es)
CO (1) CO2020004202A2 (es)
DK (1) DK3692040T3 (es)
ES (1) ES2940263T3 (es)
FI (1) FI3692040T3 (es)
HR (1) HRP20230274T1 (es)
HU (1) HUE061380T2 (es)
IL (1) IL273769A (es)
LT (1) LT3692040T (es)
MX (1) MX2020003382A (es)
PH (1) PH12020550145A1 (es)
PL (1) PL3692040T3 (es)
PT (1) PT3692040T (es)
RS (1) RS64043B1 (es)
SG (2) SG11202002771XA (es)
SI (1) SI3692040T1 (es)
WO (1) WO2019069293A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
EP3675637A4 (en) 2017-08-28 2021-05-19 Enanta Pharmaceuticals, Inc. ANTIVIRAL AGENTS AGAINST HEPATITIS B
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019246427A1 (en) * 2018-06-22 2019-12-26 Arbutus Biopharma Corporation Crystalline forms of pyridinone-containing tricyclic compounds and methods of preparing and using same
AU2019342750A1 (en) 2018-09-21 2021-04-08 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
JP2022511378A (ja) 2018-09-30 2022-01-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 縮合四環系化合物および医薬品におけるそれらの使用
AU2019385477A1 (en) 2018-11-21 2021-06-10 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN111217811B (zh) * 2018-11-26 2024-01-16 广东东阳光药业股份有限公司 稠合三环类化合物及其在药物中的应用
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN113173911A (zh) * 2021-04-20 2021-07-27 梯尔希（南京）药物研发有限公司 吡虫啉代谢物5-羟基吡虫啉的合成方法
WO2023144750A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Combination therapy for treating hepatitis b virus infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016009828A (es) * 2014-01-30 2016-10-31 Hoffmann La Roche Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b.
EP3143020B1 (en) * 2014-05-13 2019-08-21 F. Hoffmann-La Roche AG Dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US9637485B2 (en) * 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
WO2016128335A1 (en) * 2015-02-11 2016-08-18 F. Hoffmann-La Roche Ag Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017108630A1 (en) * 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
WO2018047109A1 (en) * 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals
CA3040919A1 (en) * 2016-11-07 2018-05-11 Arbutus Biopharma Corporation Substituted pyridinone-containing tricyclic compounds, and methods using same
CN106810548B (zh) * 2017-01-13 2019-02-15 苏州爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物
CN108727378A (zh) 2017-04-19 2018-11-02 银杏树药业(苏州)有限公司 新型异喹啉类化合物及其医药用途

Also Published As

Publication number Publication date
KR20200065024A (ko) 2020-06-08
AU2021203650A1 (en) 2021-07-01
RU2020118375A (ru) 2021-11-09
DK3692040T3 (da) 2023-03-13
LT3692040T (lt) 2023-04-25
CN111433206A (zh) 2020-07-17
AU2018344926A1 (en) 2020-04-16
JP7248665B2 (ja) 2023-03-29
CA3078312A1 (en) 2019-04-11
PT3692040T (pt) 2023-04-03
AU2021203650B9 (en) 2022-10-06
IL273769A (en) 2020-05-31
ES2940263T3 (es) 2023-05-04
EP3692040B1 (en) 2022-12-28
SG10202111648YA (en) 2021-11-29
BR112020006456A2 (pt) 2020-10-06
WO2019069293A1 (en) 2019-04-11
RU2020118375A3 (es) 2022-04-13
PL3692040T3 (pl) 2023-04-17
PH12020550145A1 (en) 2021-01-04
EP3692040A1 (en) 2020-08-12
US20200255428A1 (en) 2020-08-13
CN111433206B (zh) 2023-07-07
EP4180431A1 (en) 2023-05-17
RS64043B1 (sr) 2023-04-28
US20220144834A1 (en) 2022-05-12
SI3692040T1 (sl) 2023-05-31
CL2020000912A1 (es) 2021-02-19
CN116942663A (zh) 2023-10-27
HUE061380T2 (hu) 2023-06-28
HRP20230274T1 (hr) 2023-04-28
FI3692040T3 (fi) 2023-03-29
AU2021203650B2 (en) 2022-09-08
MX2020003382A (es) 2020-10-05
SG11202002771XA (en) 2020-04-29
JP2020536110A (ja) 2020-12-10

Similar Documents

Publication Publication Date Title
CL2020000912A1 (es) Compuestos químicos
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
CL2019000415A1 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih.
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201890731A1 (ru) Модуляторы корового белка гепатита b
PH12016501762A1 (en) Hepatitis b core protein allosteric modulators
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
EA201790630A1 (ru) Способы получения рибозидов
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
EA201691440A1 (ru) Производные азепана и способы лечения инфекций гепатита в
EA201691991A1 (ru) Мультиспецифические антитела
CL2017000416A1 (es) Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
CL2020002254A1 (es) Régimen posológico del modulador del ensamblaje de la cápside.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MX2018014377A (es) Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها